Molecular Partners AG Molecular Partners AG

Molecular Partners AG

MOLN

Rank in Stocks #19240
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Share Price
$2.94
Last synced: 2026-11-13
Market Cap
$109.99M
Change (1 day)
-2.33%
Change (1 year)
-28.64%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
Earnings for Molecular Partners AG (MOLN)
Earnings in Sep 2026 TTM: $-64.60M
According to Molecular Partners AG's latest financial reports, its current earnings (TTM) are $-64.60M. In 2025 the company earned $-77.69M, a decrease compared to its 2024 earnings of $-59.83M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Molecular Partners AG from 2013 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-64.60M -16.84%
2025 $-77.69M 29.85%
2024 $-59.83M -18.83%
2023 $-73.70M -157.82%
2022 $127.47M -282.21%
2021 $-69.96M 0.11%
2020 $-69.88M 86.39%
2019 $-37.49M -0.41%
2018 $-37.65M 44.29%
2017 $-26.09M 42.68%
2016 $-18.29M 12,182.08%
2015 $-148.89K -93.52%
2014 $-2.30M -128.71%
2013 $8.00M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$-57.82M -10.50%
US
$4.76B -7,467.62%
US
$-2.73B 4,124.44%
US
$-4.02B 6,117.00%
AU
$2.79B -4,424.07%
BE

Questions about Molecular Partners AG's net income

What is Molecular Partners AG's net income?

Molecular Partners AG's net income over the last twelve months is $-64.60M, as of Sep 2026.

What was Molecular Partners AG's net income in 2025?

In 2025, Molecular Partners AG's net income was $-77.69M, compared with $-59.83M in 2024.

How has Molecular Partners AG's net income changed since 2020?

From 2020 to 2025, Molecular Partners AG's net income was highest in 2022 ($127.47M) and lowest in 2025 ($-77.69M).

How does Molecular Partners AG's net income compare with similar companies?

Molecular Partners AG's net income ($-64.60M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.